8-K: Splash Beverage Group Secures Global Rights to Epilepsy Therapy

Splash Beverage Group has acquired exclusive global licensing rights for CannEpil, a cannabinoid-based epilepsy therapy, from Argent BioPharma Limited, aiming to leverage existing European access and pursue U.S. regulatory advancement.

Summary

• Splash Beverage Group (SBEV) has entered into an exclusive global licensing agreement with Argent BioPharma Limited for CannEpil, a pharmaceutical-grade cannabinoid-based investigational therapeutic for drug-resistant epilepsy (DRE).
• CannEpil is already available in international markets like Ireland, the UK, Germany, and Australia, manufactured under EU-GMP standards.
• The therapy has been prescribed through regulated patient-access programs, has established reimbursement in Europe, and has engaged with the FDA regarding its U.S. development pathway.
• Splash plans to use a $1 million strategic investment from C/M Capital Partners to support regulatory advancement, clinical development, commercialization, and strategic partnerships in the U.S.
• The transaction includes the forgiveness of approximately $5 million of Argent BioPharma indebtedness by Mercer Street Global Opportunity Fund and the issuance of $5.5 million of newly issued Splash preferred equity.
• Argent BioPharma will receive a 15% royalty on net revenue generated from worldwide sales of CannEpil.
• The agreement grants Splash exclusive worldwide commercialization rights for an initial twenty-year term, with rights to sublicense.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, as Splash Beverage Group is acquiring a promising therapeutic with existing international traction and a clear path for U.S. regulatory advancement, addressing a significant unmet medical need.

Positives

• Acquisition of exclusive global rights to CannEpil, a therapy for drug-resistant epilepsy, addressing a significant unmet medical need.
• CannEpil has existing international commercialization and patient access in multiple European countries and Australia.
• The therapy is manufactured under EU-GMP standards.
• Established reimbursement-supported access in Europe, specifically in Ireland through the Medicinal Cannabis Access Program (MCAP) and the Health Service Executive (HSE).
• Authorized for importation and prescription in the UK through the Named Patient Request framework.
• Initiated formal engagement with the U.S. Food and Drug Administration (FDA) through the pre-IND process and has an assigned Investigational New Drug (IND) number.
• Secured a $1 million strategic investment commitment from C/M Capital Partners to support U.S. development and commercialization.
• The transaction involves forgiveness of $5 million in debt and issuance of $5.5 million in preferred equity, aligning stakeholders.
• Argent BioPharma's incentive through a 15% royalty on net revenue aligns their long-term success with CannEpil's performance.

Negatives

• The company is pursuing a strategic transformation toward a cannabinoid therapeutics platform, which may involve significant execution risks.
• The company has limited staffing and needs to recommence revenue-generating activities.
• The company's ability to raise necessary capital for development and commercialization is a risk.
• Compliance with extensive regulations, including clinical testing before marketing in the U.S., presents a challenge.
• The evolving regulatory conditions within the cannabinoid and wellness industries pose a risk.

Risks

• The possibility that the license does not yield the anticipated benefits.
• Risks associated with obtaining, maintaining, or protecting intellectual property rights for CannEpil in various jurisdictions.
• Competition from companies marketing similar products.
• The company's ability to raise sufficient capital to develop and commercialize the product and meet working capital needs.
• The need to comply with extensive regulations, including clinical testing, before marketing in applicable jurisdictions, particularly the U.S.
• The status of evolving regulatory conditions within the cannabinoid and wellness industries.
• Potential challenges in recommencing revenue-generating activities with limited staffing.

Future Outlook

Splash Beverage Group intends to deploy proceeds from the strategic investment toward advancing FDA-related activities, expanding the existing clinical and real-world evidence package, engaging leading U.S. epilepsy investigators, and identifying a strategic pharmaceutical development partner to accelerate CannEpil's development in the United States and other key markets. The company believes CannEpil offers a compelling opportunity to substantially build revenue and long-term shareholder value.

Management Comments

• "The acquisition of the exclusive global rights to CannEpil is an important step in our strategy to build a differentiated cannabinoid therapeutics platform."
• "We believe CannEpil provides Splash with an exceptional opportunity to leverage existing international commercialization while pursuing U.S. regulatory advancement and strategic pharmaceutical partnerships."
• "What attracted us to CannEpil is that this is not an early-stage laboratory asset. CannEpil has already been prescribed through regulated patient-access programs, has established reimbursement-supported access in Europe, has generated meaningful real-world patient experience and has already engaged with the FDA regarding its U.S. development pathway."
• "We believe the combination of existing international utilization, regulatory progress and the significant unmet need in drug-resistant epilepsy creates a compelling opportunity to substantially build revenue and long-term shareholder value."

Industry Context

StockSavvy.ai notes that Splash Beverage Group's strategic pivot into cannabinoid therapeutics, exemplified by the acquisition of global rights to CannEpil, aligns with a broader industry trend of pharmaceutical companies exploring cannabis-derived compounds for medical applications, particularly in areas with high unmet needs like drug-resistant epilepsy. This move positions SBEV to compete in a rapidly evolving sector, though significant regulatory and development hurdles remain.

Stakeholder Impact

• Shareholders: Potential for long-term shareholder value creation through the development and commercialization of CannEpil, but also subject to risks associated with clinical development and regulatory approval.
• Creditors: Mercer Street Global Opportunity Fund, a related party, has agreed to forgive approximately $5 million of Argent BioPharma indebtedness, impacting their creditor position.
• Suppliers: Potential for increased demand for manufacturing and supply chain services related to CannEpil production.
• Employees: The company's strategic transformation may lead to changes in staffing and operational focus.

Next Steps

• Advance FDA-related activities for CannEpil.
• Expand the existing clinical and real-world evidence package for CannEpil.
• Engage leading U.S. epilepsy investigators.
• Identify a strategic pharmaceutical development partner capable of supporting future U.S.-based clinical trials.
• Develop and commercialize CannEpil in the United States and other key markets.

Key Dates

Recommendation

The acquisition of global rights to CannEpil is a significant strategic move for Splash Beverage Group, addressing a critical unmet medical need and leveraging existing international infrastructure. However, the company's transformation into a biopharmaceutical platform carries substantial execution risks, including regulatory hurdles, clinical trial success, and capital requirements. While promising, the long-term success is not guaranteed, warranting a 'hold' recommendation until further progress in U.S. regulatory advancement and commercialization is demonstrated.

Keywords

CannEpil, Splash Beverage Group, Argent BioPharma, Drug-Resistant Epilepsy, Cannabinoid Therapeutics, Epilepsy Therapy, FDA, Global Licensing, Pharmaceutical Partnerships, SBEV, Neurology